Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats

Andrologia

Volumn 44, Issue SUPPL.1, 2012, Pages 370-375

  Khalaf, M A M ^a   Abbas, M F ^a   El Fakahany, H M ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

Erectile dysfunction; PDE 5 inhibitors; Spermatogenesis; Tadalafil

Indexed keywords

SODIUM CHLORIDE; TADALAFIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL STRUCTURE; CELL VACUOLE; CONTROLLED STUDY; EPIDIDYMIS; FOOD INTAKE; HISTOPATHOLOGY; LONG TERM CARE; MALE; MICROSCOPY; MORTALITY; NONHUMAN; ORGAN WEIGHT; RAT; REPRODUCTIVE TOXICITY; SEMINIFEROUS TUBULE; SPERM; SPERMATOCYTE; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; TESTIS; TESTIS WEIGHT; TREATMENT DURATION;

ANIMALS; CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; MALE; ORGAN SIZE; PHOSPHODIESTERASE INHIBITORS; RATS; SPERM COUNT; SPERMATOZOA; TESTIS;

EID: 84861509566     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/j.1439-0272.2011.01191.x     Document Type: Article

References (23)

1. Baxendale RW, Fraser LR (2005) Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation. Mol Reprod Dev71:495-508.
2. Baxendale RW, Burslem F, Phillips SC (2001) Phosphodiesterase type 11 (PDE11) cellular localization: progress towards defining a physiological role in testis and/or reproduction. J Urol Suppl165:1395.
3. Eli Lilly and Icos Company (2005) Cialis (Tadalafil) label insert.
4. Fagelman E, Fagelman A, Shabsigh R (2001) Efficacy, safety, and use of sildenafil in urologic practice. J Urol57:1141-1144.
5. Falk JA, Philip KJ, Schwarz ER (2010) The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag6:273-280.
6. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA97:3702-3707.
7. First International Consultation on Erectile Dysfunction (1999) Sponsored by World Health Organization (WHO), International Consultation on Urological Disease (ICUD), and Société Internationale d'Urologie (SIU). Paris, 1-3 July 1999.
8. Foresta C, Pati MA, Perilli L, Menegazzo M, Zuccarello D, Ferlin A, Garolla A (2011) Expression of phosphodiesterase type 5A in human spermatozoa and influence of its inhibition on motility and functional sperm parameters. J Endocrinol Invest [Epub ahead of print].
9. Francis SH (2005) Phosphodiesterase 11 (PDE11): is it a player in human testicular function?Int J Impot Res17:467-468.
10. Hellstrom WJ, Overstreet JW, Yu A, Shen W, Beasley CM Jr, Watkins VS (2003) Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol170:887-891.
11. Hellstrom WJG, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, Watts S, Mitchell CL, McGill JM (2008) An evaluation of semen characteristics in men 45years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol53:1058-1065.
12. Hengeveld MW, Gianotten WL (2001) Erectile disorders: the realty. Eur Urol40:176-180.
13. Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC (2010) Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther334:1023-1030.
14. Ma Y, Chen B, Hu JL, Wang HX, Han YF, Wang YX, Huang YR (2009) Therapeutic effect of phosphodiesterase-5 inhibitor on pathological changes of tunica albuginea in erectile dysfunction: experiment with rats. Zhonghua Yi Xue Za Zhi89:276-279.
15. Makhlouf A, Kshirsagar A, Niederberger C (2006) Phosphodiesterase 11: a brief review of structure, expression and function. Int J Impot Res18:501-509.
16. McMahon C (2004) Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med1:292-300.
17. Mostafa T (2007) Tadalafil as an in vitro sperm motility stimulant. Andrologia39:12-15.
18. Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, de Riesthal H (2003) Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology62:400-403.
19. Paget GE, Barnes JM (1964): Evaluation of drug activities. In: Pharmacometrics. Laurence DR, Bacharach AL (eds), vol. 1: 332-381. Academic Press, New York.
20. Pomara G, Morelli G, Canale D, Turchi P, Caglieresi C, Moschini C, Liguori G, Selli C, Macchia E, Martino E, Francesca F (2007) Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. Fertil Steril88:860-865.
21. Sausen PJ, Reams RY, Morford LL, Dietsch GN (2002) Tadalafil has no effect on testes in rodents. Int J Impot Res14:S20-S32.
22. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S (2007) The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res19:139-148.
23. Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R, Burgess G (2005) Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res17:216-223.